Advertisement
YOU ARE HERE: LAT HomeCollectionsIsis Pharmaceuticals Inc
IN THE NEWS

Isis Pharmaceuticals Inc

FEATURED ARTICLES
BUSINESS
September 28, 2007 | From Times Wire Services
Isis Pharmaceuticals Inc. has acquired all outstanding shares of Symphony GenIsis for $120 million in cash and stock. Isis also reacquired full ownership of its cholesterol-lowering drug Isis 301012, the Carlsbad, Calif., company said. Symphony GenIsis was formed in April 2006 by Symphony Capital Partners to fund development of three Isis drugs.
ARTICLES BY DATE
BUSINESS
September 28, 2007 | From Times Wire Services
Isis Pharmaceuticals Inc. has acquired all outstanding shares of Symphony GenIsis for $120 million in cash and stock. Isis also reacquired full ownership of its cholesterol-lowering drug Isis 301012, the Carlsbad, Calif., company said. Symphony GenIsis was formed in April 2006 by Symphony Capital Partners to fund development of three Isis drugs.
Advertisement
BUSINESS
December 3, 2004 | From Bloomberg News
Isis Pharmaceuticals Inc. said its experimental drug alicaforsen failed as a treatment for Crohn's disease in two late-stage trials. The Carlsbad, Calif.-based biotechnology company said it would focus on getting alicaforsen approved as an enema for patients with ulcerative colitis, a use shown to be effective in phase-two studies. Isis shares rose $1.09 to $6.01 on Nasdaq.
BUSINESS
January 11, 2005 | From Bloomberg News
Isis Pharmaceuticals Inc. said Monday it planned to eliminate about 40% of its jobs to pare expenses and focus on developing a few key drugs, including an ulcerative colitis treatment. Writing down the value of assets such as equipment and patents will cost the company as much as $40 million in the fourth quarter. Additional expenses related to the firings will be recorded in the first quarter, Carlsbad, Calif.-based Isis said, without giving a specific figure.
BUSINESS
September 17, 2002 | Bloomberg News
Isis Pharmaceuticals Inc. said it and rival Sequitur Inc. have settled three patent infringement lawsuits involving biotechnology research. Terms weren't disclosed. Isis said it granted licenses for certain patents to Sequitur, which agreed to make payments to Isis and limit the types of chemistry, called antisense, it can use in research. Isis had claimed that Sequitur was using Isis technology without permission.
BUSINESS
August 28, 1998 | Washington Post
Isis Pharmaceuticals Inc. of Carlsbad has won approval to sell the first of a new kind of drug that treats disease by switching off genes. The drug, Vitravene, slows down a serious eye infection that can blind people with AIDS. The approval by the Food and Drug Administration cheered researchers who have spent three decades trying to prove that such treatments were possible.
BUSINESS
January 11, 2005 | From Bloomberg News
Isis Pharmaceuticals Inc. said Monday it planned to eliminate about 40% of its jobs to pare expenses and focus on developing a few key drugs, including an ulcerative colitis treatment. Writing down the value of assets such as equipment and patents will cost the company as much as $40 million in the fourth quarter. Additional expenses related to the firings will be recorded in the first quarter, Carlsbad, Calif.-based Isis said, without giving a specific figure.
BUSINESS
June 6, 2003
* Isis Pharmaceuticals Inc., a Carlsbad drug developer whose experimental cancer medication failed in a study, said partner Eli Lilly & Co. waived repayment of the $21-million loan used to build the manufacturing facility for the drug.
BUSINESS
September 14, 2007 | From Times Wire Reports
Johnson & Johnson will pay Isis Pharmaceuticals Inc. about $275 million to develop two drugs for diabetes, Isis said. Carlsbad-based Isis will initially receive $45 million, and may be paid $230 million or more for meeting milestones for the as-yet unnamed medicines.
BUSINESS
September 8, 2007 | From Times Wire Services
Alnylam Pharmaceuticals Inc. and Isis Pharmaceuticals Inc. have formed a venture uniting Nobel Prize winners David Baltimore and Phillip Sharp to create drugs from a newly discovered class of genetic material. The venture, Regulus Therapeutics, will have exclusive licenses from Alnylam and Isis for technology focused on so-called microRNAs. The molecules regulate networks of genes that may be involved in diseases including cancer, viral infections and metabolic disorders, the companies said.
BUSINESS
December 3, 2004 | From Bloomberg News
Isis Pharmaceuticals Inc. said its experimental drug alicaforsen failed as a treatment for Crohn's disease in two late-stage trials. The Carlsbad, Calif.-based biotechnology company said it would focus on getting alicaforsen approved as an enema for patients with ulcerative colitis, a use shown to be effective in phase-two studies. Isis shares rose $1.09 to $6.01 on Nasdaq.
BUSINESS
September 17, 2002 | Bloomberg News
Isis Pharmaceuticals Inc. said it and rival Sequitur Inc. have settled three patent infringement lawsuits involving biotechnology research. Terms weren't disclosed. Isis said it granted licenses for certain patents to Sequitur, which agreed to make payments to Isis and limit the types of chemistry, called antisense, it can use in research. Isis had claimed that Sequitur was using Isis technology without permission.
BUSINESS
August 28, 1998 | Washington Post
Isis Pharmaceuticals Inc. of Carlsbad has won approval to sell the first of a new kind of drug that treats disease by switching off genes. The drug, Vitravene, slows down a serious eye infection that can blind people with AIDS. The approval by the Food and Drug Administration cheered researchers who have spent three decades trying to prove that such treatments were possible.
BUSINESS
December 18, 2008 | times staff and wire reports
Abbott Laboratories plans to pay $175 million to complete the purchase of a company that makes sensors that government agencies and criminal detectives can use to identify germs rapidly. The drug maker will buy the 81% interest in Ibis Biosciences Inc. that is now held by Isis Pharmaceuticals Inc. Abbott earlier this year acquired 19% of Ibis, based in Carlsbad, Calif., for $40 million. The new transaction is expected to close in January, the companies said.
BUSINESS
October 2, 2002 | Denise Gellene
Carlsbad, Calif.-based Isis Pharmaceuticals Inc. said Tuesday that Eli Lilly & Co. agreed to lend it $21 million to complete a manufacturing facility for an experimental lung cancer drug. The deal expands a year-old collaboration between the firms. Isis licensed the drug, Affinitac, to Lilly in August 2001 in exchange for royalties on sales of the medication and as much as $200 million in equity, fees and milestone payments.
Los Angeles Times Articles
|